Aim Bempedoic acid is a novel oral drug, which has been increasingly researched to play
an important role in the treatment of hypercholesterolemia recently. However, results from …

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by
guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its …

Background Bempedoic acid (BA) is a novel lipid‐lowering drug. We performed a systematic
review and meta‐analysis on efficacy and safety of BA compared with standard treatment in …

Aims Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular
mortality and morbidity. Bempedoic acid represents a promising novel lipid-modifying agent …

Background Bempedoic acid is a new drug that reduces cholesterol synthesis via inhibiting
ATP citrate lyase. It remains unclear whether the combination of bempedoic acid and other …

Aim This systematic review and meta-analysis was conducted to synthesize the efficacy and
safety of bempedoic acid in patients requiring lipid-lowering therapy. Methods PubMed …

Importance Additional lipid-lowering therapy options are needed for patients who cannot
achieve sufficient decreases in low-density lipoprotein cholesterol (LDL-C) levels using …

Bempedoic acid has proven beneficial for further reduction of LDL cholesterol for targeted
groups of patients. It is not only efficient but also a well tolerated, affordable, and available …

Background and aims Bempedoic acid significantly lowers low-density lipoprotein
cholesterol (LDL-C) in patients with hypercholesterolemia but its effects in patients with …

The central role of high low-density lipoprotein cholesterol levels in atherosclerotic
cardiovascular disease has led to research focused on lipid-lowering agents for …